Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview
This article will illustrate the low risk of immune response to AAV serotype 2 vector-mediated gene therapy to the brain with support from clinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.PMID:34551695 | DOI:10.2174/1566523221666210922155413
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Wuh-Liang Hwu Shin-Ichi Muramatsu Bruria Gidoni-Ben-Zeev Source Type: research
More News: Adenoviruses | Brain | Clinical Trials | Gene Therapy | Genetics | Neurology | Parkinson's Disease